tetano
Editor, Senior Moderator
Front Immunol. 2015 Apr 21;6:170. doi: 10.3389/fimmu.2015.00170. eCollection 2015.
[h=1]Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.[/h] Li J[SUP]1[/SUP], Diaz-Ar?valo D[SUP]1[/SUP], Chen Y[SUP]1[/SUP], Zeng M[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus is a negative segmented RNA virus without DNA intermediate. This makes it safer as a vaccine delivery vector than most DNA viruses that have potential to integrate their genetic elements into host genomes. In this study, we developed a universal influenza viral vector, expressing the receptor binding subdomain of botulinum neurotoxin A (BoNT/A). We tested the growth characters of the engineered influenza virus in chicken eggs and Madin-Darby canine kidney epithelial cells (MDCK), and showed that it can be produced to a titer of 5 ? 10(6) plaque forming unites/ml in chicken eggs and MDCK cells. Subsequently, mice intranasally vaccinated with the engineered influenza virus conferred protection against challenge with lethal doses of active BoNT/A toxin and influenza virus. Our results demonstrated the feasibility to develop a dual purpose nasal vaccine against both botulism and influenza.
[h=4]KEYWORDS:[/h] botulinum neurotoxin; influenza; intranasal vaccination; protective immunity; recombinant influenza vector
PMID: 25954272 [PubMed]
[h=1]Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.[/h] Li J[SUP]1[/SUP], Diaz-Ar?valo D[SUP]1[/SUP], Chen Y[SUP]1[/SUP], Zeng M[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus is a negative segmented RNA virus without DNA intermediate. This makes it safer as a vaccine delivery vector than most DNA viruses that have potential to integrate their genetic elements into host genomes. In this study, we developed a universal influenza viral vector, expressing the receptor binding subdomain of botulinum neurotoxin A (BoNT/A). We tested the growth characters of the engineered influenza virus in chicken eggs and Madin-Darby canine kidney epithelial cells (MDCK), and showed that it can be produced to a titer of 5 ? 10(6) plaque forming unites/ml in chicken eggs and MDCK cells. Subsequently, mice intranasally vaccinated with the engineered influenza virus conferred protection against challenge with lethal doses of active BoNT/A toxin and influenza virus. Our results demonstrated the feasibility to develop a dual purpose nasal vaccine against both botulism and influenza.
[h=4]KEYWORDS:[/h] botulinum neurotoxin; influenza; intranasal vaccination; protective immunity; recombinant influenza vector
PMID: 25954272 [PubMed]